...
首页> 外文期刊>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders >An Observational 1-Month Trial on the Efficacy and Safety of Promerim for Improving Knee Joint
【24h】

An Observational 1-Month Trial on the Efficacy and Safety of Promerim for Improving Knee Joint

机译:1个月产前改善膝关节疗效和安全性观察性试验

获取原文
           

摘要

Objective: This study was conducted to evaluate the efficacy and tolerability of the oral intake of promerim in the elimination of acute pain and discomfort associated with knee osteoarthritis (OA). Methods: Single-center, 1-month, prospective, observational clinical trial. A total of 92 patients not older than 70?years were included. Patients were offered to use 720-mg promerim for the first 15?days after admission after breakfast and then 360?mg for the second 15?days. All patients were analyzed with the visual analog scale (VAS) for pain, which ranges from 0 to 10, and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score before the start of treatment and 1?month after the start. Statistical analysis was performed by SPSS 15.0 software. An α level of P ?
机译:目的:本研究旨在评估口服宝美林在消除与膝骨关节炎(OA)有关的急性疼痛和不适中的功效和耐受性。方法:单中心,1个月,前瞻性,观察性临床试验。总共包括92名不超过70岁的患者。早餐后入院后的前15天,患者可使用720 mg promerim,然后第二15天,可使用360 mg。所有患者均在治疗开始前和开始后1个月使用视觉模拟量表(VAS)进行疼痛评估,范围为0至10,以及西安大略省和麦克马斯特大学的骨关节炎指数(WOMAC)评分。统计分析通过SPSS 15.0软件进行。假定α水平P≤<0.05。结果:这项研究包括92例患者(69名女性和23名男性),平均年龄为51.5岁(范围:40-69岁)。治疗前,VAS评分平均为5.6?±?1.1,治疗后,VAS平均评分为2.6?±?1.7。早孕素治疗一直显示VAS评分显着降低(P <0.001)。治疗前患者的平均WOMAC评分为46.4±±8.2。治疗后,WOMAC的平均评分为72.1±14.4。早孕素治疗一直显示WOMAC评分显着增加(P <0.001)。结论:这项单中心,开放标签的临床研究结果表明,promerim是治疗膝骨关节炎的可行的自然疗法。我们建议在入院后的头15天每天服用720 mg早孕素,然后在接下来的15天里每天服用360mg早孕素,可在1个月内显着并迅速减少膝盖OA的复合疼痛和僵硬。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号